China is advancing weapons that could incapacitate the United States without any military action. They have gained a significant foothold in global drug development, and now, their influence over medical innovations that Americans rely on is notable.
Currently, Chinese firms are behind nearly a third of all drugs in development, and they’ve recently overtaken the U.S. in the number of clinical trials conducted. By 2040, China is projected to contribute over a third of new FDA approvals.
If any of these trials yield crucial breakthroughs, like treatments for cancer or vaccines during pandemics, China could leverage that to negotiate terms with the U.S. It’s a risk the United States can’t afford. We must cultivate a biotechnology sector that can compete effectively and is independent from China.
Our primary goal should be to stop the foreign free-riding that is progressively undermining the U.S. biotech industry.
For many years, wealthier nations have implemented price controls to limit what they spend on innovative medicines. As a result, pharmaceutical companies often find it challenging to recover the exorbitant costs involved in research and development (often surpassing $2.6 billion for a single new drug), leading them to transfer much of that financial burden onto the U.S. market.
This situation has created a global disparity. Although the U.S. is a leader in medical innovation, American patients frequently pay significantly more than those in other countries for identical drugs.
This inequity isn’t just unjust; it also renders U.S. biotech more susceptible. When foreign governments underpay for American-developed drugs, they effectively drain revenue from U.S. innovators, hampering their ability to invest in necessary research and manufacturing to stay ahead of China.
The United States must insist that its trade partners pay their fair share. A vital first step is to initiate an investigation under Section 301 concerning unjust drug pricing practices by other nations. This action would signal the serious intent of the U.S. government to end free riding and unlock broader trade enforcement measures to bring foreign nations to the negotiating table.
Following that, the U.S. could pursue additional agreements, similar to President Trump’s recent arrangement with the UK, where the UK committed to higher payments for innovative drugs. If other affluent countries like Japan and Germany followed suit, it would provide stronger financial support for U.S. biotech and allow domestic prices to drop.
At the same time, lawmakers should avoid merely mirroring price controls from other nations. Such actions wouldn’t end the free ride; instead, they’d reinforce it, leading to detrimental impacts on innovation.
Implementing foreign-style price caps would likely compel pharmaceutical companies to limit their research and development efforts, allowing China to take the lead on future treatments. It would also diminish the U.S.’s negotiating leverage, making it extremely difficult to achieve fair prices internationally.
There are more effective strategies to assist policymakers in lowering drug costs. If foreign nations cease free-riding, prices will likely decrease naturally.
China’s increasing dominance in biotechnology represents a significant strategic concern. Yet, there is still time to address this issue.
If American decision-makers act promptly, bolstering the biotechnology sector and curtailing foreign free-riding will enable the U.S. to remain competitive and continue to spearhead medical innovations globally.
